Trial Profile
Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GSK
- 12 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 12 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2010 New trial record